Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18946175
Takemori H, et al. (2009) Inactivation of HDAC5 by SIK1 in AICAR-treated C2C12 myoblasts. Endocr J 56, 121-30 18946175
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S21-p - GSK3A (rat)
Modsite: SGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
indirubin no change compared to control
acadesine no change compared to control

S9-p - GSK3B (rat)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
indirubin no change compared to control
acadesine no change compared to control

Y216-p - GSK3B (rat)
Modsite: RGEPNVsyICsRyYR SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): Y216‑p, GSK3B iso2 (human): Y216‑p, GSK3B (mouse): Y216‑p, GSK3B (rat): Y216‑p, GSK3B (rabbit): Y216‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
Cellular systems studied:  cell lines
Species studied:  mouse

T182-p - SIK (rat)
Modsite: KPGEPLStWCGsPPY SwissProt Entrez-Gene
Orthologous residues
SIK (human): T182‑p, SIK (mouse): T182‑p, SIK (rat): T182‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (rat)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
acadesine increase
indirubin acadesine inhibit treatment-induced increase
indirubin decrease
acadesine increase
serum acadesine inhibit treatment-induced increase
LY294002 acadesine inhibit treatment-induced increase
serum decrease

S186-p - SIK (rat)
Modsite: PLStWCGsPPYAAPE SwissProt Entrez-Gene
Orthologous residues
SIK (human): S186‑p, SIK (mouse): S186‑p, SIK (rat): S186‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  C2C12 (myoblast)
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (rat)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
acadesine increase
indirubin acadesine inhibit treatment-induced increase
indirubin decrease
acadesine increase
serum acadesine inhibit treatment-induced increase
LY294002 acadesine inhibit treatment-induced increase
serum decrease